All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Inotuzumab ozogamicin receives U.S. FDA approval for pediatric patients aged ≥1 year with CD22+ R/R B-ALL

Mar 8, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL

Bookmark this article

On March 6, 2024, it was announced that the U.S. Food and Drug Administration (FDA) had approved inotuzumab ozogamicin for the treatment of pediatric patients aged 1 year and older with relapsed/refractory (R/R) CD22-positive B-cell precursor acute lymphoblastic leukemia (B-ALL). This approval is based on results from a multicenter, single-arm, open-label study.

The study included a total of 53 patients who were evaluated at two dose levels: (1) initial dose of 1.4 mg/m2/cycle (n = 12); and (2) 1.8 mg/m2/cycle (n = 41).

The key outcomes were as follows:

  • A complete remission (CR) rate of 42% was achieved in all patients.
  • A median duration of CR of 8.2 months was demonstrated.
  • An MRD negativity rate of 95.5% was reported based on flow cytometry and 86.4% based on real-time quantitative polymerase chain reaction for patients who achieved a CR.
  • The most commonly reported adverse reactions were: thrombocytopenia, pyrexia, anemia, vomiting, infection, hemorrhage, neutropenia, nausea, leukopenia, febrile neutropenia, increased transaminases, abdominal pain, and headache.

For the first cycle, the U.S. FDA has recommended an inotuzumab ozogamicin dose of 1.8 mg/m2 per cycle given as 3 fractionated doses on Day 1 (0.8 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2).

  1. S. Food & Drug Administration. FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia. Published March 6, 2024. Accessed March 7, 2024.


Subscribe to get the best content related to ALL delivered to your inbox